The adhesion molecule ICAM-1 is overexpressed in patients with hymenoptera venom allergy and decreases after ultrarush venom immunotherapy

Journal of Biological Regulators and Homeostatic Agents

Volumn 25, Issue 3, 2011, Pages 465-468

  Patella, V ^a   Incorvaia, Cristoforo ^b   Ricciardi, L ^c   Florio, G ^a   Saija, A ^c   Frati, F ^d   Gangemi, S ^c,e  

^a Agropoli Hospital   (Italy)

^b ICP Hospital   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d Medical and Scientific Department   (Italy)

^e CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

Hymenoptera venom allergy; ICAM 1; Venom immunotherapy

Indexed keywords

BEE VENOM; HYMENOPTERA VENOM; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VENOM; YELLOW JACKET VENOM;

ADULT; ALLERGY; ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYMENOPTERA VENOM ALLERGY; IMMUNOTHERAPY; MALE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; ANIMALS; BEE VENOMS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYMENOPTERA; HYPERSENSITIVITY; IMMUNOTHERAPY; INFLAMMATION; INSECT BITES AND STINGS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-4; MALE; MIDDLE AGED; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA; WASP VENOMS;

APIS MELLIFERA; HYMENOPTERA;

EID: 80755159115     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Ciprandi G, Buscaglia S, Pesce G, et al. Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. J Allergy Clin Immunol 1995; 96:971-79.
2. Reisman RE. Stinging insect allergy. Med Clin North Am 1992; 76:883-94.
3. Romagnani S. Cytokines and chemoattractants in allergic inflammation. Mol Immunol 2002; 38:881-85. (Pubitemid 34496945)
4. Nicholson IC. CD62L (L-selectin). J Biol Regul Homeost Agents 2002; 16:144-46.
5. Kelly M, Hwang JM, Kubes P. Modulating leukocytes recruitment in inflammation. J Allergy Clin Immunol 2007; 120:3-10.
6. Passalacqua G, Albano M, Riccio A, et al. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: a double-blind, placebo-controlled trial. J Allergy Clin Immunol 1999; 104:964-68. (Pubitemid 29532116)
7. Patella V, Florio G, Spadaro G. Hymenoptera venom allergy: A new ultra-rush immunotherapy. In: Cellular and Molecular Targets in Allergy and Clinical Immunology. Holgate ST, Marone G, Ring J. (Eds) Hogrefe and Huber Publishers 2008, vol. 179, no. 3, pp. 354.
8. Bousquet J, Lockey R, Mailing HJ, et al. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. J Allergy Clin Immunol 1998; 102:558-62.
9. Ciprandi G, Tosca MA, Marseglia GL. Sublingual immunotherapy mechanisms of action: the role of ThI response. Int J Immunopathol Pharmacol 2009; 22(S):9-12.
10. Larché M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nature Rev Immunol 2006; 10:761-71. (Pubitemid 44453462)
11. Akdis CA, Akdis M. Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. J Allergy Clin Immunol 2009; 123:735-46.
12. McHugh SM, Deighton J, Stewart AG, Lachmann PJ, Ewan PW. Bee venom immunotherapy induces a shift in cytokine responses from a Th2 to a Th1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy 1995; 25:828-38.
13. Schuerwegh AJ, De Clerck LS, Bridts CH, Stevens WJ. Wasp venom immunotherapy induces a a shift from IL-4 producing towards interferon-gamma- producing CD4+ and CD8+ T lymphocytes. Clin Exp Allergy 2001; 31:740-46. (Pubitemid 32823818)
14. Bussmann C, Xia J, Allam JP, Maintz L, Bieber T, Novak N. Early markers for protective mechanism during rush venom immunotherapy. Allergy 2010; 65:1558-65.
15. Striz I, Mio T, Adachi Y, et al. IL-4 induces ICAM-1 expression in human bronchial epithelial cells and potentiates TNF-alpha. Am J Physiol 1999; 277:58-64.